Channel Therapeutics Inc. (PTHS): Total Asset Value of Company

The price trajectory of Channel Therapeutics (PTHS) demonstrates the company's dependence on available reserves, as Channel Therapeutics (PTHS) does not yet have profitable products and total assets amount to 69.13. The business focuses on developing peptide drugs to treat brain disorders. Patents and strict FDA oversight create a high barrier to entry, complicating the expansion of new players into this sector.

Channel Therapeutics (PTHS) Company Total Assets: for the period 07/03/2025 - 10/28/2026

Comprehensive metric breakdowns and analytics for Channel (PTHS)

- price and consensus price forecast:

Market Chart channeltherapeutics.com|PTHS - Price Target Chart

- market capitalization data:

Market Valuation Channel Pharma|PTHS - Enterprise Value

- book capitalization data:

Accounting Value of a Share Channel Therapeutics|PTHS - Book Capitalization|Market Capitalization to Book Value Ratio channeltherapeutics.com|PTHS - Aggregate Company Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Channel Therapeutics|PTHS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Channel Pharma|PTHS - Company Aggregate Debts|Debts to Book Capitalization Channel Pharma|PTHS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Channel Therapeutics

Fundamental valuation:PTHS, channeltherapeutics.com

Finished products of Channel Therapeutics

Total assets, reverse-calculated via ROA, reflect the aggregate resource potential of the business and its ability to offset inflationary pressure on costs. By analyzing the magnitude of consolidated assets, an investor assesses capital resilience to market shocks, which is critical for Channel Therapeutics (PTHS) amid the fierce battle for patents with leaders in the neurological segment.

Competitors of Channel Therapeutics (PTHS)

JAZZ (jazzpharma.com) - Company Total Asset Base|Aggregate Company Assets Cytokinetics, Incorporated CYTK|Total Asset Value of Company PTC Therapeutics Inc|Scholar Rock Corp (SRRK) - Company Total Assets|Aggregate Asset Value Centessa Corp (CNTA)|Company Total Assets DYN (Dyne Therapeutics, Inc.)|edgewisetx.com - Company Total Assets|Aggregate Company Assets Rapport Therapeutics (RAPP)|ALMS: Aggregate Asset Value|ZVRA (Kempharm) - Aggregate Company Assets|Contineum Corp (CTNM) - Cumulative Company Assets|LRMR (Larimar Therapeutics) - Company Total Assets|Company Total Assets Capricor (CAPR)|Entrada Therapeutics, Inc. (TRDA) - Cumulative Company Assets|Aggregate Asset Value MNOV (medicinova.com)|SER - Aggregate Company Assets|Total Business Assets BioXcel Therapeutics Corp BTAI|PMN (ProMIS) - Company Total Assets|Apimeds Pharmaceuticals (APUS) - Company Assets|AEON: Cumulative Company Assets|NLSP (NLS Pharmaceutics) - Company Total Assets|BNOX - Aggregate Company Assets|Aggregate Asset Value HUGE|Reata Pharmaceuticals - Aggregate Company Assets